163 related articles for article (PubMed ID: 32176332)
1. The prevalence and demographic determinants of blood donors receiving testosterone replacement therapy at a large USA blood service organization.
Hazegh K; Bravo MD; Kamel H; Dumont L; Kanias T
Transfusion; 2020 May; 60(5):947-954. PubMed ID: 32176332
[TBL] [Abstract][Full Text] [Related]
2. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy.
Lundy SD; Parekh NV; Shoskes DA
J Sex Med; 2020 Jul; 17(7):1297-1303. PubMed ID: 32307242
[TBL] [Abstract][Full Text] [Related]
3. Blood donation and testosterone replacement therapy.
Chin-Yee B; Lazo-Langner A; Butler-Foster T; Hsia C; Chin-Yee I
Transfusion; 2017 Mar; 57(3):578-581. PubMed ID: 28150363
[TBL] [Abstract][Full Text] [Related]
4. Toxic masculinity in red blood cell units? Testosterone therapy in blood donors revisited.
Hazegh K; Anawalt BD; Dumont LJ; Kanias T
Transfusion; 2021 Nov; 61(11):3174-3180. PubMed ID: 34519056
[TBL] [Abstract][Full Text] [Related]
5. Testosterone replacement therapy in blood donors modulates erythrocyte metabolism and susceptibility to hemolysis in cold storage.
Alexander K; Hazegh K; Fang F; Sinchar D; Kiss JE; Page GP; DʼAlessandro A; Kanias T
Transfusion; 2021 Jan; 61(1):108-123. PubMed ID: 33073382
[TBL] [Abstract][Full Text] [Related]
6. Erythrocytosis and Polycythemia Secondary to Testosterone Replacement Therapy in the Aging Male.
Jones SD; Dukovac T; Sangkum P; Yafi FA; Hellstrom WJ
Sex Med Rev; 2015 Apr; 3(2):101-112. PubMed ID: 27784544
[TBL] [Abstract][Full Text] [Related]
7. Effect of testosterone replacement therapy on sexual function and glycemic control among hypogonadal men with type 2 diabetes mellitus.
Shigehara K; Konaka H; Kato Y; Iijima M; Nakashima K; Kawaguchi S; Nohara T; Izumi K; Namiki M; Mizokami A
Int J Impot Res; 2019 Jan; 31(1):25-30. PubMed ID: 30135606
[TBL] [Abstract][Full Text] [Related]
8. Marketing and Testosterone Treatment in the USA: A Systematic Review.
Bandari J; Ayyash OM; Emery SL; Wessel CB; Davies BJ
Eur Urol Focus; 2017 Oct; 3(4-5):395-402. PubMed ID: 29174614
[TBL] [Abstract][Full Text] [Related]
9. Testosterone replacement therapy use among active component service men, 2017.
Larsen E; Clausen S; Stahlman S
MSMR; 2019 Mar; 26(3):26-31. PubMed ID: 30912666
[TBL] [Abstract][Full Text] [Related]
10. Effect of increasing hemoglobin cutoff in male donors and increasing interdonation interval in whole blood donors at a hospital-based blood donor center.
Gandhi MJ; Duffy K; Benike M; Jenkins S; Stubbs JR
Transfusion; 2012 Sep; 52(9):1880-8. PubMed ID: 22313024
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Phlebotomy for Testosterone-Induced Polycythemia.
Van Buren NL; Hove AJ; French TA; Gorlin JB
Am J Clin Pathol; 2020 Jun; 154(1):33-37. PubMed ID: 32134468
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of testosterone replacement in men with obesity: a systematic review and meta-analysis.
Mangolim AS; Brito LAR; Nunes-Nogueira VDS
Eur J Endocrinol; 2021 Dec; 186(1):123-135. PubMed ID: 34738915
[TBL] [Abstract][Full Text] [Related]
13. Testosterone replacement therapy (TRT) and its effect on bone marrow. How serious is it and is there a true polyglobulia?
Levcikova M; Breza J; Luha J; Dubravicky J; Kovacova E; Fillo J
Bratisl Lek Listy; 2017; 118(11):654-657. PubMed ID: 29216720
[TBL] [Abstract][Full Text] [Related]
14. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters.
Yassin A; Nettleship JE; Talib RA; Almehmadi Y; Doros G
Aging Male; 2016; 19(1):64-9. PubMed ID: 26742589
[TBL] [Abstract][Full Text] [Related]
15. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
[TBL] [Abstract][Full Text] [Related]
16. Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.
Okada K; Miyake H; Ishida T; Sumii K; Enatsu N; Chiba K; Matsushita K; Fujisawa M
Am J Mens Health; 2018 Sep; 12(5):1403-1408. PubMed ID: 27256990
[TBL] [Abstract][Full Text] [Related]
17. Effects of intermission and resumption of long-term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle-aged and elderly men.
Yassin A; Almehmadi Y; Saad F; Doros G; Gooren L
Clin Endocrinol (Oxf); 2016 Jan; 84(1):107-14. PubMed ID: 26331709
[TBL] [Abstract][Full Text] [Related]
18. Effect of a national disaster on blood supply and safety: the September 11 experience.
Glynn SA; Busch MP; Schreiber GB; Murphy EL; Wright DJ; Tu Y; Kleinman SH;
JAMA; 2003 May; 289(17):2246-53. PubMed ID: 12734136
[TBL] [Abstract][Full Text] [Related]
19. Risk of Erythrocytosis During Concomitant Testosterone and SGLT2-Inhibitor Treatment: A Warning From Two Clinical Cases.
Motta G; Zavattaro M; Romeo F; Lanfranco F; Broglio F
J Clin Endocrinol Metab; 2019 Mar; 104(3):819-822. PubMed ID: 30395251
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
